Omnicell (NASDAQ:OMCL) Releases FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 1.650-1.850 for the period, compared to the consensus estimate of 1.780. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its Q1 2025 guidance to 0.150-0.250 EPS.

Omnicell Price Performance

Shares of Omnicell stock traded up $0.56 during trading hours on Tuesday, reaching $35.52. 117,795 shares of the company's stock were exchanged, compared to its average volume of 517,158. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.75. The company has a market capitalization of $1.66 billion, a P/E ratio of 131.73, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The business has a fifty day moving average of $38.86 and a two-hundred day moving average of $42.52.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, research analysts predict that Omnicell will post 1.09 earnings per share for the current fiscal year.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Bank of America dropped their target price on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research report on Monday, January 6th. Wells Fargo & Company dropped their price target on Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. StockNews.com downgraded Omnicell from a "buy" rating to a "hold" rating in a research report on Monday, March 24th. Benchmark reiterated a "buy" rating and set a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. reduced their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, Omnicell has a consensus rating of "Hold" and an average target price of $51.00.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.